ClinicalTrials.gg
TerminatedNCT04003610Updated Nov 4, 2025Results posted

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

A Phase 2 interventional study of Pemigatinib and Pembrolizumab in Metastatic Urothelial Carcinoma and Unresectable Urothelial Carcinoma, sponsored by Incyte Corporation. Terminated at 79 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-04.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

Why this study was terminated
The reason this study was terminated was due to a business decision. There were no safety concerns that contributed to this decision.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
7
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing pembrolizumab in Carcinoma, Transitional Cell — 9 open to participants now, 13 under way, 3 of them phase 3. pembrolizumab · Carcinoma, Transitional Cell.

Enrollment
22nd of 28
7 · median 31
Started
2020
with 3 others
Phase 2
19 of 28
6 open now
Registered
13th of 28
by date

Among the 28 studies testing pembrolizumab in Carcinoma, Transitional Cell, this one is the 22nd largest by enrollment, is one of 4 that started in 2020, is one of 19 in phase 2, and was the 13th registered.

Carcinoma, Transitional Cell

632 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

9 of the 28 studies testing pembrolizumab in Carcinoma, Transitional Cell are open now, in 4 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing pembrolizumab in Carcinoma, Transitional Cell, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus pembrolizumab or pemigatinib alone versus the standard of care for participants with metastatic or unresectable urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received prior treatment.

03

Conditions studied

  • Metastatic Urothelial Carcinoma
  • Unresectable Urothelial Carcinoma

Keywords

  • Urothelial carcinoma
  • fibroblast growth factor receptor (FGFR) inhibitor
  • FGFR3 mutation
  • FGFR3 rearrangement
  • metastatic
  • unresectable
  • cisplatin-ineligible
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • documented or unresectable urothelial carcinoma. Both transitional cell and mixed transitional cell histologies are allowed, provided urothelial component is ≥ 50%.
  • At least 1 measurable target lesion per v1.1.
  • Must be ineligible to receive cisplatin. Patients ineligible for any platinum-based chemotherapy are allowed.
  • Known FGFR3 mutation or rearrangement confirmed by the central laboratory prior to randomization.
  • Central laboratory test result of status is mandatory at screening.
  • Have received no prior systemic chemotherapy for metastatic or unresectable urothelial carcinoma (except platinum-based chemotherapy following radical cystectomy, with recurrence > 12 months from completion of therapy, or neo-adjuvant platinum-based chemotherapy, with recurrence > 12 months since completion of therapy).
  • (ECOG) performance status 0 to 2.
  • Willingness to avoid pregnancy or fathering children.

Exclusion criteria

Exclusion Criteria:

  • Prior receipt of a selective FGFR inhibitor for any indication or reason.
  • Prior receipt of an , anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another co-inhibitory T-cell receptor.
  • Receipt of anticancer medications or drugs for unresectable and/or disease.
  • Concurrent anticancer therapy, except for treatment allowed per protocol.
  • Has disease that is suitable for local therapy administered with curative intent.
  • Has tumor with any neuroendocrine or small cell component.
  • Current evidence of corneal or retinal disorder as confirmed by ophthalmologic examination.
  • Has received prior radiotherapy to a metastatic site without the use of chemotherapy radiosensitization within 3 weeks of the first dose of study treatment, with the exception of palliative radiotherapy to bone lesions, which is allowed if completed 2 weeks before the start of study treatment.
  • Has central nervous system metastases, unless the participant has completed local therapy (eg, whole brain radiation therapy, surgery, radiosurgery) and has discontinued use of for this indication for at least 4 weeks before starting treatment in this study.
  • Known additional that is progressing or required active treatment within the past 3 years
  • Laboratory values outside the protocol-defined range at screening.
  • Clinically significant or uncontrolled cardiac disease.
  • History of disease that has required systemic treatment in past 2 years.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Pemigatinib + Pembrolizumab

    Combination of pemigatinib (13.5 milligrams \[mg\] once a day orally) plus pembrolizumab (200 mg every 3 weeks \[Q3W\] intravenously \[IV\])

    Drug: Pemigatinib · Drug: Pembrolizumab

  • Experimental
    Pemigatinib

    Pemigatinib (13.5 mg once a day orally) alone

    Drug: Pemigatinib

  • Active comparator
    Standard of Care

    Either gemcitabine plus carboplatin or pembrolizumab as standard of care. Gemcitabine 1000 mg/meters squared (m\^2) IV over 30 minutes on Days 1 and 8, followed by carboplatin (dosed to target area under the concentration-time curve \[AUC\] of 5 mg/milliliters \[mL\]/minute \[min\] or 4.5 mg/mL/min if required per local guidelines) on Day 1 or 2 of each 3-week cycle. Pembrolizumab 200 mg IV on Day 1 of each 21-day treatment cycle for up to 35 cycles or disease progression.

    Drug: Gemcitabine · Drug: Carboplatin

Interventions

  • 13.5 mg once a day orally

    Also known as: INCB054828

  • 200 mg Q3W intravenously

    Also known as: Keytruda®

  • 1000 mg/m\^2 IV over 30 minutes on Days 1 and 8 of each 3-week cycle

  • Dosed to target AUC of 5 mg/mL/min or 4.5 mg/mL/min if required per local guidelines on Day 1 or 2 of each 3-week cycle

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    PFS was defined as the time from the randomization date until the date of disease progression (as measured by a blinded independent central review \[BICR\] per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v1.1\]) or death due to any cause, whichever occurred first.

    Time frame: up to 130 days

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from the date of randomization until death due to any cause.

    Time frame: up to 225 days

  2. Objective Response Rate (ORR)

    ORR was defined as the proportion of participants with a best overall response of complete response (CR) or partial response (PR) per RECIST v1.1 (as measured by BICR).

    Time frame: up to 148 days

  3. Duration of Response (DOR)

    DOR was defined as the time from the date of the first assessment of CR or PR until the date of the first disease progression (per RECIST v1.1) or death, whichever occurred first (as measured by BICR).

    Time frame: up to 148 days

  4. Number of Participants With Treatment-emergent Adverse Events

    A treatment-emergent adverse event was defined as an adverse event that was either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until 30 days after the last dose of study drug.

    Time frame: up to 178 days

  5. EORTC QLQ-C30 Score

    The European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) contains 30 items and measures 5 functional dimensions (i.e., physical, role, emotional, cognitive, and social), 3 symptom items (i.e., fatigue, nausea/vomiting, and pain), 6 single items (i.e., dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial impact), and a global health and quality of life scale. For each scale and single item, a linear transformation was applied to standardize the scores between 0 (worst) and 100 (best) as described in the EORTC QLQ-C30 Scoring Manual.

    Time frame: up to 160 days

  6. Change From Baseline in the EORTC QLQ-C30 Score

    The European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) contains 30 items and measures 5 functional dimensions (i.e., physical, role, emotional, cognitive, and social), 3 symptom items (i.e., fatigue, nausea/vomiting, and pain), 6 single items (i.e., dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial impact), and a global health and quality of life scale. For each scale and single item, a linear transformation was applied to standardize the scores between 0 (worst) and 100 (best) as described in the EORTC QLQ-C30 Scoring Manual. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; up to 160 days

  7. Number of Participants With the Indicated EQ-5D-5L Dimension Scores

    The EQ-5D-5L is a standardized instrument for use as a measure of health outcome. The EQ-5D-5L descriptive system is composed of 5 dimensions (mobility, self-case, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 5 response levels, which are coded by single-digit numbers: 1 = no problems, 2 = slight problems, 3 = moderate problems, 4 = severe problems, 5 = unable to/extreme problems. The EQ-5D-5L also includes a graded (0 \[worst overall health\] to 100 \[best overall health\]) vertical visual analog scale that provides a quantitative measure of the participant's perception of their overall health.

    Time frame: up to 160 days

  8. Change From Baseline in the EQ-5D-5L EQ Visual Analog Scale Score

    The EQ-5D-5L is a standardized instrument for use as a measure of health outcome. The EQ-5D-5L descriptive system is composed of 5 dimensions (mobility, self-case, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 5 response levels, which are coded by single-digit numbers: 1 = no problems, 2 = slight problems, 3 = moderate problems, 4 = severe problems, 5 = unable to/extreme problems. The EQ-5D-5L also includes a graded (0 \[worst overall health\] to 100 \[best overall health\]) vertical visual analog scale that provides a quantitative measure of the participant's perception of their overall health.

    Time frame: Baseline; up to 160 days

07

Results

Posted May 25, 2022
Limitations and caveats
The Sponsor made a decision unrelated to safety to halt study enrollment. Due to early termination of the study with only 7 participants, no analysis of efficacy endpoints was done.

Participant flow

This study was conducted (enrolled participants) at 7 sites located in France, Italy, Spain, and Japan.

Participant flow — Overall Study
MilestonePemigatinib 13.5 mgPemigatinib 13.5 mg Plus Pembrolizumab 200 mgGemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mg
Started016
Completed000
Not completed016
Withdrew: Lost to follow-up010
Withdrew: Death003
Withdrew: Study terminated by sponsor003

Outcome measures

PrimaryProgression-free Survival (PFS)

PFS was defined as the time from the randomization date until the date of disease progression (as measured by a blinded independent central review \[BICR\] per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v1.1\]) or death due to any cause, whichever occurred first.

Time frame:
up to 130 days
Reported as:
Median · months
Progression-free Survival (PFS)
monthsPemigatinib 13.5 mgPemigatinib 13.5 mg Plus Pembrolizumab 200 mgGemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mg
Progression-free Survival (PFS)—1.81 (NA to NA)2.12 (1.51 to NA)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of randomization until death due to any cause.

Time frame:
up to 225 days
Reported as:
Median · months
Overall Survival (OS)
monthsPemigatinib 13.5 mgPemigatinib 13.5 mg Plus Pembrolizumab 200 mgGemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mg
Overall Survival (OS)—NA (NA to NA)NA (1.51 to NA)
SecondaryObjective Response Rate (ORR)

ORR was defined as the proportion of participants with a best overall response of complete response (CR) or partial response (PR) per RECIST v1.1 (as measured by BICR).

Time frame:
up to 148 days
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsPemigatinib 13.5 mgPemigatinib 13.5 mg Plus Pembrolizumab 200 mgGemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mg
Objective Response Rate (ORR)—00
SecondaryDuration of Response (DOR)

DOR was defined as the time from the date of the first assessment of CR or PR until the date of the first disease progression (per RECIST v1.1) or death, whichever occurred first (as measured by BICR).

Time frame:
up to 148 days

No measurements were reported for this outcome.

SecondaryNumber of Participants With Treatment-emergent Adverse Events

A treatment-emergent adverse event was defined as an adverse event that was either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until 30 days after the last dose of study drug.

Time frame:
up to 178 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events
ParticipantsPemigatinib 13.5 mgPemigatinib 13.5 mg Plus Pembrolizumab 200 mgGemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mg
Number of Participants With Treatment-emergent Adverse Events—16
SecondaryEORTC QLQ-C30 Score

The European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) contains 30 items and measures 5 functional dimensions (i.e., physical, role, emotional, cognitive, and social), 3 symptom items (i.e., fatigue, nausea/vomiting, and pain), 6 single items (i.e., dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial impact), and a global health and quality of life scale. For each scale and single item, a linear transformation was applied to standardize the scores between 0 (worst) and 100 (best) as described in the EORTC QLQ-C30 Scoring Manual.

Time frame:
up to 160 days
Reported as:
Mean · scores on a scale
EORTC QLQ-C30 Score
scores on a scalePemigatinib 13.5 mgPemigatinib 13.5 mg Plus Pembrolizumab 200 mgGemcitabine 1000 mg/m^2 Plus carboplatinGemcitabine 1000 mg/m^2 Plus Carboplatin
Appetite Loss, Baseline—33.3 ± NA26.7 ± 36.51
Appetite Loss, Cycle 3 Day 1——16.7 ± 23.57
Appetite Loss, Cycle 6 Day 1——0.0 ± NA
Appetite Loss, Follow Up——66.7 ± NA
Cognitive Functioning, Baseline—66.7 ± NA66.7 ± 20.41
Cognitive Functioning, Cycle 3 Day 1——91.7 ± 11.79
Cognitive Functioning, Cycle 6 Day 1——66.7 ± NA
Cognitive Functioning, Follow Up——83.3 ± NA
Constipation, Baseline—0.0 ± NA40.0 ± 27.89
Constipation, Cycle 3 Day 1——16.7 ± 23.57
Constipation, Cycle 6 Day 1——0.0 ± NA
Constipation, Follow Up——33.3 ± NA
Diarrhea, Baseline—0.0 ± NA20.0 ± 44.72
Diarrhea, Cycle 3 Day 1——0.0 ± 0.0
Diarrhea, Cycle 6 Day 1——0.0 ± NA
Diarrhea, Follow Up——33.3 ± NA
Dyspnea, Baseline—0.0 ± NA26.7 ± 27.89
Dyspnea, Cycle 3 Day 1——16.7 ± 23.57
Dyspnea, Cycle 6 Day 1——33.3 ± NA
Dyspnea, Follow Up——66.7 ± NA
Emotional Functioning, Baseline—50.0 ± NA73.3 ± 19.00
Emotional Functioning, Cycle 3 Day 1——87.5 ± 5.89
Emotional Functioning, Cycle 6 Day 1——91.7 ± NA
Emotional Functioning, Follow Up——100.0 ± NA
Fatigue, Baseline—44.4 ± NA46.7 ± 36.35
Fatigue, Cycle 3 Day 1——50.0 ± 39.28
Fatigue, Cycle 6 Day 1——33.3 ± NA
Fatigue, Follow Up——55.6 ± NA
Financial Difficulties, Baseline—33.3 ± NA20.0 ± 18.26
Financial Difficulties, Cycle 3 Day 1——16.7 ± 23.57
Financial Difficulties, Cycle 6 Day 1——0.0 ± NA
Financial Difficulties, Follow Up——0.0 ± NA
Global Health Status/Quality of Life (QoL), Baseline—16.7 ± NA51.7 ± 31.95
Global Health Status/QoL, Cycle 3 Day 1——66.7 ± 11.79
Global Health Status/QoL, Cycle 6 Day 1——66.7 ± NA
Global Health Status/QoL, Follow Up——50.0 ± NA
Insomnia, Baseline—33.3 ± NA46.7 ± 38.01
Insomnia, Cycle 3 Day 1——33.3 ± 47.14
Insomnia, Cycle 6 Day 1——0.0 ± NA
Insomnia, Follow Up——66.7 ± NA
Nausea and Vomiting, Baseline—0.0 ± NA6.7 ± 9.13
Nausea and Vomiting, Cycle 3 Day 1——8.3 ± 11.79
Nausea and Vomiting, Cycle 6 Day 1——0.0 ± NA
Nausea and Vomiting, Follow Up——16.7 ± NA
Pain, Baseline—50.0 ± NA40.0 ± 43.46
Pain, Cycle 3 Day 1——41.7 ± 11.79
Pain, Cycle 6 Day 1——0.0 ± NA
Pain, Follow Up——16.7 ± NA
Physical Functioning, Baseline—73.3 ± NA65.3 ± 26.83
Physical Functioning, Cycle 3 Day 1——33.3 ± 47.14
Physical Functioning, Cycle 6 Day 1——66.7 ± NA
Physical Functioning, Follow Up——40.0 ± NA
Role Functioning, Baseline—66.7 ± NA56.7 ± 40.14
Role Functioning, Cycle 3 Day 1——33.3 ± 47.14
Role Functioning, Cycle 6 Day 1——66.7 ± NA
Role Functioning, Follow Up——33.3 ± NA
Social Functioning, Baseline—66.7 ± NA53.3 ± 36.13
Social Functioning, Cycle 3 Day 1——66.7 ± 0.00
Social Functioning, Cycle 6 Day 1——66.7 ± NA
Social Functioning, Follow Up——83.3 ± NA
SecondaryChange From Baseline in the EORTC QLQ-C30 Score

The European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) contains 30 items and measures 5 functional dimensions (i.e., physical, role, emotional, cognitive, and social), 3 symptom items (i.e., fatigue, nausea/vomiting, and pain), 6 single items (i.e., dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial impact), and a global health and quality of life scale. For each scale and single item, a linear transformation was applied to standardize the scores between 0 (worst) and 100 (best) as described in the EORTC QLQ-C30 Scoring Manual. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; up to 160 days
Reported as:
Mean · scores on a scale
Change From Baseline in the EORTC QLQ-C30 Score
scores on a scalePemigatinib 13.5 mgPemigatinib 13.5 mg Plus Pembrolizumab 200 mgGemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mg
Appetite Loss, Cycle 3 Day 1——-16.7 ± 23.57
Appetite Loss, Cycle 6 Day 1——0.0 ± NA
Appetite Loss, Follow Up——0.0 ± NA
Cognitive Functioning, Cycle 3 Day 1——33.3 ± 23.57
Cognitive Functioning, Cycle 6 Day 1——0.0 ± NA
Cognitive Functioning, Follow Up——33.3 ± NA
Constipation, Cycle 3 Day 1——-33.3 ± 0.00
Constipation, Cycle 6 Day 1——-33.3 ± NA
Constipation, Follow Up——-33.3 ± NA
Diarrhea, Cycle 3 Day 1——-50.0 ± 70.71
Diarrhea, Cycle 6 Day 1——0.0 ± NA
Diarrhea, Follow Up——-66.7 ± NA
Dyspnea, Cycle 3 Day 1——0.0 ± 0.00
Dyspnea, Cycle 6 Day 1——33.3 ± NA
Dyspnea, Follow Up——33.3 ± NA
Emotional Functioning, Cycle 3 Day 1——12.5 ± 29.46
Emotional Functioning, Cycle 6 Day 1——0.0 ± NA
Emotional Functioning, Follow Up——41.7 ± NA
Fatigue, Cycle 3 Day 1——-11.1 ± 15.71
Fatigue, Cycle 6 Day 1——11.1 ± NA
Fatigue, Follow Up——-44.4 ± NA
Financial Difficulties, Cycle 3 Day 1——0.0 ± 0.00
Financial Difficulties, Cycle 6 Day 1——0.0 ± NA
Financial Difficulties, Follow Up——-33.3 ± NA
Global Health Status/QoL, Cycle 3 Day 1——33.3 ± 35.36
Global Health Status/QoL, Cycle 6 Day 1——16.7 ± NA
Global Health Status/QoL, Follow Up——33.3 ± NA
Insomnia, Cycle 3 Day 1——-16.7 ± 23.57
Insomnia, Cycle 6 Day 1——0.0 ± NA
Insomnia, Follow Up——-33.3 ± NA
Nausea and Vomiting, Cycle 3 Day 1——0.0 ± 0.00
Nausea and Vomiting, Cycle 6 Day 1——0.0 ± NA
Nausea and Vomiting, Follow Up——0.0 ± NA
Pain, Cycle 3 Day 1——-8.3 ± 58.93
Pain, Cycle 6 Day 1——0.0 ± NA
Pain, Follow Up——-83.3 ± NA
Physical Functioning, Cycle 3 Day 1——-26.7 ± 37.71
Physical Functioning, Cycle 6 Day 1——0.0 ± NA
Physical Functioning, Follow Up——-13.3 ± NA
Role Functioning, Cycle 3 Day 1——0.0 ± 0.00
Role Functioning, Cycle 6 Day 1——0.0 ± NA
Role Functioning, Follow Up——33.3 ± NA
Social Functioning, Cycle 3 Day 1——41.7 ± 11.79
Social Functioning, Cycle 6 Day 1——33.3 ± NA
Social Functioning, Follow Up——66.7 ± NA
SecondaryNumber of Participants With the Indicated EQ-5D-5L Dimension Scores

The EQ-5D-5L is a standardized instrument for use as a measure of health outcome. The EQ-5D-5L descriptive system is composed of 5 dimensions (mobility, self-case, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 5 response levels, which are coded by single-digit numbers: 1 = no problems, 2 = slight problems, 3 = moderate problems, 4 = severe problems, 5 = unable to/extreme problems. The EQ-5D-5L also includes a graded (0 \[worst overall health\] to 100 \[best overall health\]) vertical visual analog scale that provides a quantitative measure of the participant's perception of their overall health.

Time frame:
up to 160 days
Reported as:
Count of participants · Participants
Number of Participants With the Indicated EQ-5D-5L Dimension Scores
ParticipantsPemigatinib 13.5 mgPemigatinib 13.5 mg Plus Pembrolizumab 200 mgGemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mg
Anxiety/Depression, Baseline — 1—03
Anxiety/Depression, Baseline — 2—00
Anxiety/Depression, Baseline — 3—11
Anxiety/Depression, Baseline — 4—01
Anxiety/Depression, Baseline — 5—00
Anxiety/Depression, Cycle 4 Day 1 — 1——1
Anxiety/Depression, Cycle 4 Day 1 — 2——0
Anxiety/Depression, Cycle 4 Day 1 — 3——0
Anxiety/Depression, Cycle 4 Day 1 — 4——0
Anxiety/Depression, Cycle 4 Day 1 — 5——0
Anxiety/Depression, Cycle 7 Day 1 — 1——1
Anxiety/Depression, Cycle 7 Day 1 — 2——0
Anxiety/Depression, Cycle 7 Day 1 — 3——0
Anxiety/Depression, Cycle 7 Day 1 — 4——0
Anxiety/Depression, Cycle 7 Day 1 — 5——0
Anxiety/Depression, Follow Up — 1——1
Anxiety/Depression, Follow Up — 2——0
Anxiety/Depression, Follow Up — 3——0
Anxiety/Depression, Follow Up — 4——0
Anxiety/Depression, Follow Up — 5——0
Mobility, Baseline — 1—01
Mobility, Baseline — 2—02
Mobility, Baseline — 3—12
Mobility, Baseline — 4—00
Mobility, Baseline — 5—00
Mobility, Cycle 4 Day 1 — 1——0
Mobility, Cycle 4 Day 1 — 2——1
Mobility, Cycle 4 Day 1 — 3——0
Mobility, Cycle 4 Day 1 — 4——0
Mobility, Cycle 4 Day 1 — 5——0
Mobility, Cycle 7 Day 1 — 1——0
Mobility, Cycle 7 Day 1 — 2——1
Mobility, Cycle 7 Day 1 — 3——0
Mobility, Cycle 7 Day 1 — 4——0
Mobility, Cycle 7 Day 1 — 5——0
Mobility, Follow Up — 1——0
Mobility, Follow Up — 2——0
Mobility, Follow Up — 3——0
Mobility, Follow Up — 4——0
Mobility, Follow Up — 5——1
Pain/Discomfort, Baseline — 1—02
Pain/Discomfort, Baseline — 2—01
Pain/Discomfort, Baseline — 3—10
Pain/Discomfort, Baseline — 4—02
Pain/Discomfort, Baseline — 5—00
Pain/Discomfort, Cycle 4 Day 1 — 1——1
Pain/Discomfort, Cycle 4 Day 1 — 2——0
Pain/Discomfort, Cycle 4 Day 1 — 3——0
Pain/Discomfort, Cycle 4 Day 1 — 4——0
Pain/Discomfort, Cycle 4 Day 1 — 5——0
Pain/Discomfort, Cycle 7 Day 1 — 1——0
Pain/Discomfort, Cycle 7 Day 1 — 2——0
Pain/Discomfort, Cycle 7 Day 1 — 3——1
Pain/Discomfort, Cycle 7 Day 1 — 4——0
Pain/Discomfort, Cycle 7 Day 1 — 5——0
Pain/Discomfort, Follow Up — 1——0
Pain/Discomfort, Follow Up — 2——0
Pain/Discomfort, Follow Up — 3——1
Pain/Discomfort, Follow Up — 4——0
Pain/Discomfort, Follow Up — 5——0
Self-care, Baseline — 1—03
Self-care, Baseline — 2—10
Self-care, Baseline — 3—02
Self-care, Baseline — 4—00
Self-care, Baseline — 5—00
Self-care, Cycle 4 Day 1 — 1——0
Self-care, Cycle 4 Day 1 — 2——1
Self-care, Cycle 4 Day 1 — 3——0
Self-care, Cycle 4 Day 1 — 4——0
Self-care, Cycle 4 Day 1 — 5——0
Self-care, Cycle 7 Day 1 — 1——0
Self-care, Cycle 7 Day 1 — 2——1
Self-care, Cycle 7 Day 1 — 3——0
Self-care, Cycle 7 Day 1 — 4——0
Self-care, Cycle 7 Day 1 — 5——0
Self-care, Follow Up — 1——0
Self-care, Follow Up — 2——0
Self-care, Follow Up — 3——1
Self-care, Follow Up — 4——0
Self-care, Follow Up — 5——0
Usual Activities, Baseline — 1—02
Usual Activities, Baseline — 2—01
Usual Activities, Baseline — 3—12
Usual Activities, Baseline — 4—00
Usual Activities, Baseline — 5—00
Usual Activities, Cycle 4 Day 1 — 1——0
Usual Activities, Cycle 4 Day 1 — 2——1
Usual Activities, Cycle 4 Day 1 — 3——0
Usual Activities, Cycle 4 Day 1 — 4——0
Usual Activities, Cycle 4 Day 1 — 5——0
Usual Activities, Cycle 7 Day 1 — 1——0
Usual Activities, Cycle 7 Day 1 — 2——1
Usual Activities, Cycle 7 Day 1 — 3——0
Usual Activities, Cycle 7 Day 1 — 4——0
Usual Activities, Cycle 7 Day 1 — 5——0
Usual Activities, Follow Up — 1——0
Usual Activities, Follow Up — 2——0
Usual Activities, Follow Up — 3——0
Usual Activities, Follow Up — 4——1
Usual Activities, Follow Up — 5——0
SecondaryChange From Baseline in the EQ-5D-5L EQ Visual Analog Scale Score

The EQ-5D-5L is a standardized instrument for use as a measure of health outcome. The EQ-5D-5L descriptive system is composed of 5 dimensions (mobility, self-case, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 5 response levels, which are coded by single-digit numbers: 1 = no problems, 2 = slight problems, 3 = moderate problems, 4 = severe problems, 5 = unable to/extreme problems. The EQ-5D-5L also includes a graded (0 \[worst overall health\] to 100 \[best overall health\]) vertical visual analog scale that provides a quantitative measure of the participant's perception of their overall health.

Time frame:
Baseline; up to 160 days
Reported as:
Mean · scores on a scale
Change From Baseline in the EQ-5D-5L EQ Visual Analog Scale Score
scores on a scalePemigatinib 13.5 mgPemigatinib 13.5 mg Plus Pembrolizumab 200 mgGemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mg
Baseline—40 ± NA52 ± 30.54
Cycle 4 Day 1——5 ± NA
Cycle 7 Day 1——5 ± NA
Follow Up——30 ± NA

Adverse events

Collected over up to 178 days. Deaths were monitored for up to 225 days. Treatment-emergent adverse events (TEAEs) were monitored for up to 178 days (for up to 30 days after last dose of study drug).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemigatinib 13.5 mg———
Pemigatinib 13.5 mg Plus Pembrolizumab 200 mg0/1 (0%)1/1 (100%)1/1 (100%)
Gemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mg3/6 (50%)1/6 (16.7%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventPemigatinib 13.5 mgPemigatinib 13.5 mg Plus Pembrolizumab 200 mgGemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mg
Bone painMusculoskeletal and connective tissue disorders—1/10/6
COVID-19Infections and infestations—0/11/6
Most frequent other events
Showing 10 of 35
Most frequent other events
EventPemigatinib 13.5 mgPemigatinib 13.5 mg Plus Pembrolizumab 200 mgGemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mg
Alanine aminotransferase increasedInvestigations—1/11/6
Aspartate aminotransferase increasedInvestigations—1/10/6
Erythema multiformeSkin and subcutaneous tissue disorders—1/10/6
HyperphosphataemiaMetabolism and nutrition disorders—1/10/6
HypertransaminasaemiaHepatobiliary disorders—1/10/6
StomatitisGastrointestinal disorders—1/10/6
ConstipationGastrointestinal disorders—0/13/6
AstheniaGeneral disorders—0/12/6
Blood alkaline phosphatase increasedInvestigations—0/12/6
MalaiseGeneral disorders—0/12/6

Baseline characteristics

No participants were enrolled in the pemigatinib 13.5 mg treatment arm.

Age, Customized
Age, Customized(Participants)Pemigatinib 13.5 mgPemigatinib 13.5 mg Plus Pembrolizumab 200 mgGemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mgTotal
57 to 84 years old0167
Sex: Female, Male
Sex: Female, Male(Participants)Pemigatinib 13.5 mgPemigatinib 13.5 mg Plus Pembrolizumab 200 mgGemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mgTotal
Female—NA4NA
Male—NA2NA
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pemigatinib 13.5 mgPemigatinib 13.5 mg Plus Pembrolizumab 200 mgGemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mgTotal
Hispanic or Latino—NA0NA
Not Hispanic or Latino—NA5NA
Unknown or Not Reported—NA1NA
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pemigatinib 13.5 mgPemigatinib 13.5 mg Plus Pembrolizumab 200 mgGemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mgTotal
American Indian or Alaska Native—NA0NA
Asian—NA3NA
Native Hawaiian or Other Pacific Islander—NA0NA
Black or African American—NA0NA
White—NA3NA
More than one race—NA0NA
Unknown or Not Reported—NA0NA
08

Study locations

79 sites
  • Marin Cancer Care
    Greenbrae, California 94904, United States
  • Christiana Care Helen F. Graham Cancer Center
    Newark, Delaware 19713, United States
  • Cotton-O'Neil Clinical Research Center, Hematology & Oncology
    Marietta, Georgia 30067, United States
  • Simmons Cancer Institute At Siu
    Springfield, Illinois 62702, United States
  • The University of Kansas Cancer Center
    Westwood, Kansas 66205, United States
  • Smhc Cancer Blood Disorders
    Biddeford, Maine 04005, United States
  • Summit Medical Group
    Florham Park, New Jersey 07932, United States
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Charleston Hematology Oncology Associates
    Charleston, South Carolina 29414, United States
  • Vanderbilt-Ingram Cancer Center
    Nashville, Tennessee 37232, United States
  • The Center For Cancer and Blood Disorders
    Fort Worth, Texas 76104, United States
  • Onc Consultants Pharmacy 2
    Houston, Texas 77030, United States
  • Wilhelminenspital
    Vienna, 01160, Austria
  • Grand Hopital de Charleroi
    Charleroi, 06000, Belgium
  • Universitaire Ziekenhuis Leuven - Gasthuisberg
    Leuven, 03000, Belgium
  • Moncton Hospital - Horizon Health Network
    Moncton, New Brunswick E1C 6Z8, Canada
  • Helsinki University Meilahti Tower Hospital
    Helsinki, 00029, Finland
  • Fonk Onkologian Klinikka
    Tampere, 33520, Finland
  • Turku University Hospital, Sct Unit
    Turku, 20521, Finland
  • Centre Hospitalier Universitaire de Besancon
    Besançon, 25000, France
  • Groupe Hospitalier Pellegrin Tripode
    Bordeaux, 33075, France
  • Polyclinique de Blois
    La Chaussée-Saint-Victor, 41260, France
  • Chu Nimes
    Nîmes, 30029, France
  • Groupe Hospitalier Pitie-Salpetriere
    Paris, 75013, France
  • Hopital Cochin Cancerologie
    Paris, 75014, France
  • Hopital Europeen Georges Pompidou (Hegp)
    Paris, 75015, France
  • Centre Hospitalier Universitaire de Poitiers
    Poitiers, 86021, France
  • Chu de Strasbourg Hopitaux Universitaires Service D Hematologie
    Strasbourg, 67091, France
  • Institut Claudius Regaud Oncopole Toulouse
    Toulouse, 31100, France
  • Kliniken Maria Hilf
    Mönchengladbach, 41063, Germany
  • University Hospital Waterford
    Waterford, X91 ER8E, Ireland
  • Iov - Istituto Oncologico Veneto Irccs
    Bari, 70124, Italy
  • Istituto Tumori Giovanni Paolo Ii Irccs Ospedale Oncologico Bari
    Bari, 70124, Italy
  • L AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA POLICLINICO S. ORSOLA � MALPIGHI
    Bologna, 40138, Italy
  • Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori
    Meldola, 47014, Italy
  • Fondazione Irccs Ca Granda Ospedale Maggiore
    Milan, 20122, Italy
  • Fondazione Irccs Istituto Nazionale Dei Tumori
    Milan, 20133, Italy
  • Ieo Istituto Europeo Di Oncologia Irccs
    Milan, 20141, Italy
  • Istituto Nazionale Tumori Fondazione Irccs G. Pascale
    Naples, 80131, Italy
  • UNIVERSIT� CAMPUS BIO-MEDICO DI ROMA
    Roma, 00128, Italy
  • Irrcs Instituto Clinico Humanitas
    Rozzano, 20089, Italy
  • Azosp S.Maria Sc Oncologia
    Terni, 05100, Italy
  • Chiba University Hospital
    Chiba, 260-8677, Japan
  • Chiba Cancer Center
    Chiba, 260-8717, Japan
  • National Hospital Organization Kyushu Cancer Center
    Fukuoka, 811-1395, Japan
  • Saitama Medical University International Medical Center
    Hidaka-shi, 350-1298, Japan
  • Hirosaki University Hospital
    Hirosaki-shi, 036-8563, Japan
  • Hakodate Goryokaku Hospital
    Hokkaido, 040-8611, Japan
  • Sapporo Medical University Hospital
    Hokkaido, 060-8543, Japan
  • Nihon University Itabashi Hospital
    Itabashi-ku, 173-8610, Japan
  • Nara Medical University Hospital
    Kashihara-shi, 634-8522, Japan
  • St. Marianna University School of Medicine Hospital
    Kawasaki-shi, 216-8511, Japan
  • Kagawa University Hospital
    Kita-gun, 761-0793, Japan
  • Nho Shikoku Cancer Center
    Matsuyama, 791-0280, Japan
  • Toranomon Hospital
    Minatoku, 105-8470, Japan
  • Osaka International Cancer Institute
    Osaka, 541-8567, Japan
  • Saitama Medical Center Jichi Medical University
    Saitama-shi, 330-8503, Japan
  • Tohoku University Hospital
    Sendai, 980-8574, Japan
  • Jichi Medical University Hospital
    Shimotsuke-shi, 329-0498, Japan
  • Keio University Hospital
    Shinjuku-ku, 160-8582, Japan
  • Osaka University Hospital
    Suita-shi, 565-0871, Japan
  • National Cancer Center Hospital
    Tokyo, 104-0045, Japan
  • Toyama University Hospital
    Toyama, 930-0194, Japan
  • Olsztynski Osrodek Onkologiczny Kopernik
    Olsztyn, 10-513, Poland
  • Champalimaud Foundation - Champalimaud Centre For the Unknown (Champalimaud Cancer Center)
    Lisbon, 1400-048, Portugal
  • Spitalul Clinic Judetean de Urgenta 'Sf Apostol Andrei' Constanta
    Constanța, 900591, Romania
  • Fakultna Nemocnica S Poliklinikou Zilina
    Žilina, 01207, Slovakia
  • Hospital Clinic I Provincial
    Barcelona, 08036, Spain
  • Ico Institut Catala D Oncologia
    Barcelona, 08908, Spain
  • Ico Girona
    Girona, 17007, Spain
  • Hospital Clinico San Carlos
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario de La Paz
    Madrid, 28046, Spain
  • Hospital Universitario Hm Sanchinarro
    Madrid, 28050, Spain
  • Hospital Puerta de Hierro
    Majadahonda, 28222, Spain
  • Hospital Universitario Virgen Del Rocio
    Seville, 41013, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, 46010, Spain
  • Barts Health Nhs Trust - St Bartholomews Hospital
    London, EC1A 7BE, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2020 to primary completion in Apr 2021, 11 months.

Results were first posted in May 2022, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2019
First posted
Jul 1, 2019
StartActual
May 14, 2020
Primary completionActual
Apr 18, 2021
CompletionActual
Apr 18, 2021
Results first posted
May 25, 2022
Last update
Nov 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04003610
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Jul 1, 2019
Start date
May 14, 2020
Primary completion
Apr 18, 2021
Completion
Apr 18, 2021
Results posted
May 25, 2022
Last update
Nov 4, 2025

Study contacts

Luis Feliz Vinas, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pemigatinib · Pembrolizumab

Start the discussion